IP Library Patent Application 16870637
Patent Application
App. No. 16/870,637

Methods of Manufacturing Cannabidiol or Cannabidivarin and Intermediates of Manufacturing Cannabidiol or Cannabidivarin

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/870,637
Abstract

Methods of manufacturing cannabidiol (CBD) and cannabidivarin (CBDV); intermediates of the methods of manufacturing CBD and CBDV; and crystallized CBD and CBDV obtained via described methods.

Claims (28)

1 . A method of manufacturing cannabidiol (CBD) comprising the following steps:

a) reacting p-mentha-2,8-diene-1-ol (PMD) with 6-carboxymethyl olivetol (CMO) and a catalyst in the presence of an organic solvent to produce (1′R,2′R)-methyl 2,6-dihydroxy-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxylate (CMCBD);

b) distilling CMCBD to obtain a distilled CMCBD;

c) reacting the distilled CMCBD with water, methanol and sodium hydroxide to produce a CBD; and

d) purifying the CBD from step (c) to obtain a purified CBD.

2 . The method of claim 1 , wherein the catalyst comprises a compound selected from boron trifluoride (BF 3 )-etherate, scandium triflate, scandium chloride, ytterbium triflate, ytterbium chloride, tin chloride, titanium chloride aluminum trichloride, magnesium bromide as well as partial or fully substituted alkyl, alkoxy, phenyl or phenoxy derivatives of the same.

3 . The method of claim 1 , wherein step (d) comprises crystallization and wherein the purified CBD is a crystallized CBD.

4 . The method of claim 1 , wherein the molar ratio of PMD to CMO in step (a) is from 1:1 to 10:1.

5 . The method of claim 1 , wherein PMD is at at least 30% molar excess compared to CMO.

6 . The method of claim 1 , wherein step (a) is carried out at a temperature from 10° C. to 30° C.

7 . The method of claim 1 , wherein the organic solvent in step (a) is selected from dichloromethane, ethyl acetate, chloroform, methyl tert-butyl ether, cyclohexane, toluene, ethyl alcohol, methyl alcohol, isopropyl alcohol, n-butyl alcohol, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, methyl tert-butyl ether, cyclohexane, water and mixtures thereof.

8 . The method of claim 1 , wherein the distilled CBD obtained in step (b) has a purity of at least 95%.

9 . The method of claim 1 , wherein step (b) is carried out at a temperature from 10° C. to 30° C.

10 . The method of claim 1 , wherein step (b) comprises thin film evaporation process.

11 . The method of claim 1 , wherein the molar ratio of CMCBD and water in step (c) is from 1:1 to 1:100.

12 . The method of claim 1 , wherein the molar ratio of methanol and sodium hydroxide in step (c) is from 1:1 to 1:100.

13 . The method of claim 3 , wherein step (d) comprises using hexane and/or pentane as a crystallization solvent.

14 . The method of claim 3 , wherein the crystallized CBD obtained in step (d) has a purity of at least 99%.

15 . The method of claim 3 , wherein the crystallized CBD obtained in step (d) has the following crystal size distribution: between 250 μm and 1000 μm, with average size of the crystal being 500 μm.

16 . A crystallized CBD manufactured by the method of claim 3 .

17 . A compound of the following structure:

18 . A method of manufacturing cannabidivarin (CBDV) comprising the following steps:

a) reacting p-mentha-2,8-diene-1-ol (PMD) with 6-carboxymethyl divinarol (CMD) and a catalyst in the presence of an organic solvent to produce (1′R,2′R)-methyl 2,6-dihydroxy-5′-methyl-4-propyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-3-carboxylate (CMCBDV);

b) distilling CMCBDV to obtain a distilled CMCBDV;

c) reacting the distilled CMCBDV with water, methanol and sodium hydroxide to produce a CBDV; and

d) purifying the CBDV from step (c) to obtain a purified CBDV.

19 . The method of claim 18 , wherein step (d) comprises crystallization and wherein the purified CBDV is a crystallized CBDV.

20 . A crystallized CBDV manufactured by the method of claim 19 .

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: BENUVIA MANUFACTURING, LLC
To: BENUVIA OPERATIONS, LLC
Reel/Frame 061190/0187 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FINANCIAL TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0938 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FUNDING IV TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0914 →
SECURITY AGREEMENT SUPPLEMENT (REVOLVING) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 055632/0634 →
SECURITY AGREEMENT SUPPLEMENT (TERM) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 055632/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: FRESH CUT DEVELOPMENT, LLC
To: BENUVIA MANUFACTURING, LLC
Reel/Frame 055246/0236 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: MITCHELL, JIM; PRINCE, PATRICK
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 052966/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: INSYS DEVELOPMENT COMPANY, INC.; INSYS THERAPEUTICS, INC; INSYS PHARMA, INC.
To: FRESH CUT DEVELOPMENT, LLC
Reel/Frame 052966/0923 →